Currently, there are only a few AMPs in clinical development for the treatment of local skin (bovine indolicidin), nasal (synthetic antimicrobial peptidomimetic Lytixar (LTX-109)), or oral (LL-37) bacterial infections, all of which are intended for topical use at the site of infection. Here, ADSL is linked to infection.